Bright Minds Biosciences Inc. Common Stock (DRUG)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable advantages and honest numbers. Bright Minds is a clinical-stage biotech with 26 employees, developing serotonin agonists and BMB-101 for epilepsy and neuropsychiatric disorders. It has no commercial product and no revenue growth data in the figures provided. The balance sheet shows no debt, with D/E of 0.00, and FairStock’s Altman Z-Score is 208.99, so solvency is not the immediate concern. But cash generation is negative: trailing free cash flow is -$24.7M and FairStock’s FCF yield is -2.8%. FairStock’s ROE is -13.63% and ROCE is -13.50%, indicating the enterprise currently consumes capital rather than earns a return on it. The Piotroski F-Score of 3/9 confirms weak fundamental momentum. Valuation is speculative: at the 2026-10-13 close of $51.36, the market cap is $882.3M; FairStock’s P/E is -25.55 and P/B is 2.31. A negative P/E means there are no positive trailing earnings to anchor value, and the 52-week range of $47.23 to $123.75 shows how violently sentiment can move. Beta of -0.11 is unusual but not a moat. The Lynch category is none because FairStock only finds 0 years of filed annual results, needing 3. A clinical-stage biotech has no durable moat until approvals, patents, and commercial execution prove it. Growth depends on BMB-101 phase 2 trials and other pipeline candidates. I would want trial data, cash runway, and dilution risk before calling this investment-grade. The price offers no margin of safety on current numbers.

In plain English: Bright Minds Biosciences is a small healthcare company with 26 employees that develops experimental drugs for severe epilepsy and brain-related conditions. It does not yet make steady profits and spends cash on clinical trials, so its current financial results are negative. At $51.36, the market value is about $882 million, which looks rich compared with today’s numbers, though a successful drug could change that picture.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer